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Abstract
Objectives: The significance of clonal evolution and derivative chromosome 9 in Philadelphia-positive CML is not
fully characterized and studies have yielded conflicting results. After working on emergence of clonal evolution from
our region, we continued to find out the response of Imatinib Mesylate on such cases of CML treated in our center.
Materials and methods: We conducted a cross sectional, prospective analysis on response of Imatinib Mesylate
on patients with Philadelphia positive chronic myeloid leukemia with clonal evolution treated from period of
September 2007 till 2010. Patients were grouped on basis of cytogenetic analysis performed by conventional
cytogenetic and fluorescence in situ hybridization (FISH) techniques and followed for three years to see the
response rate of imatinib mesylate.
Results: We reported here the response rate in one hundred and two previously untreated cases of chronic
myeloid leukemia (Philadelphia positive). Twelve patients (11.7%) exhibit derivative chromosome 9, three had
trisomy 8, one with addition 15 and one had deletion 16. At follow-up of 30 months 78 cases were evaluable and
45% and 61% showed complete and major cytogenetic response respectively. There is no significant association of
derivative chromosome 9 with the response of imatinib mesylate in our group.
Conclusion: Imatinib mesylate is the first line therapy in chronic phase of CML but the role in patients with clonal
evolution need to be established by larger group of patients.
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Introduction
Chronic Myeloid Leukemia (CML) is a clonal hematologic
malignancy that arises in the stem cell compartment [1-3]. Its
molecular hallmark is the BCR-ABL fusion gene, [4,5] which usually
occurs as the result of the Philadelphia (Ph) translocation involving
the long arms of chromosomes 9 and 22 [6].
The development of Fluorescence In Situ Hybridization (FISH)
techniques has allowed identification of unexpected deletions of the
reciprocal translocation product, the derivative chromosome 9, in 10%
to 15% of patients with CML [4,5]. These deletions are large, and occur
at the same time as the Ph translocation. Such deletions therefore give
rise to unsuspected molecular heterogeneity from the very beginning
of this disease. Several studies have demonstrated that CML patients
who carry derivative chromosome 9 deletions exhibit a more rapid
progression to blast crisis and a shorter survival [7]. Deletion status is
independent and more powerful than the Sokal and Hasford/European
prognostic scoring systems [7].
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On the other hand, the emergence of non-random chromosomal
abnormalities or aberrations in addition to the Ph chromosome is a
well-recognized occurrence in CML and is referred to Clonal
Evolution (CE). CE may be a marker of disease progression in CML
and is thought to reflect the genetic instability of the highly
proliferative CML progenitors.
Regardless of the underlying mechanisms, the net result of clonal
evolution is the potential for a more malignant phenotype and,
possibly, less dependence on BCR-ABL for proliferation and survival
[8,9]. Given its association with disease progression, CE is considered
a feature that defines accelerated-phase CML. Clonal evolution that
seen frequently in CML include extra Ph chromosome, trisomy 8,
trisomy 19, and isochromosome 17q (with loss of p53) or 20q deletion
[10,11]. Among them, isochromosome 17q abnormality carries the
worst prognosis [7]. Trisomy 8 is commonly occurring abnormality; in
25% of CML cases with clonal evolution has significance in blast
transformation of disease [12].
Imatinib mesylate, STI571, an oral, specific inhibitor of the BCRABL tyrosine kinase, was well tolerated and had substantial activity
against CML [12] but the role in cases with clonal evolution needs to
be established.
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This study will be helpful to determine the prevalence and
prognostic significance of clonal evolution abnormalities in our cohort
of patients. The detection of these chromosomal abnormalities is
important; as on this basis we would be able to stratify the patients
into good or bad prognostic groups and will be able to offer them
suitable treatment option in our setting.
The aims and objectives of our study were to observe the
occurrence of non-random chromosomal abnormalities, clonal
evolution; other than or in addition to Philadelphia chromosome 9,
chromosome 22 (q34; q11) in Chronic Myeloid Leukemia (CML) at
time of presentation by using conventional cytogenetic and FISH
(Fluorescence In Situ Hybridization) and to identify new cytogenetic
aberration or clonal evolution in patients receiving treatment.
In addition; we tried to correlate the prognostic significance of these
clonal evolutions and their association or impact on response of
imatinib mesylate treatment.

Materials and Methods
This was a prospective cross sectional analysis extending from
September 2007 till September 2010. The study population was
comprised of all patients with Ph and/or BCR/ABL positive CML
(chronic phase according to WHO criteria [12], of all age groups and
both sex treated with imatinib mesylate at Aga Khan University
Hospital (supported by MAX foundation) after obtaining informed
consent.
The MAX foundation is a USA based NGO who provides Imatinib
mesylate to needy patients in developing countries. Aga Khan
University Hospital is registered with Max foundation and in this
study all of our patients were supported by this foundation.
The patients who had Philadelphia chromosome negative, or
BCR/ABL negative myeloproliferative disorder or who were diagnosed
as in accelerated or blast phase of the disease were not included in this
study.
The diagnosis of CML was based on characteristic peripheral blood
smear and bone marrow examination findings after reviewing the
slides and was confirmed by the presence of Philadelphia chromosome
on bone marrow cytogenetic analysis by conventional cytogenetic or
detection of BCR/ABL translocation by Fluorescence In Situ
Hybridization (FISH). Patients were grouped on basis of clonal
evolution identified and were followed for three years to assess the
response of imatinib mesylate.

Molecular Pathology of the Aga Khan University Hospital, Karachi,
Pakistan.
The response of imatinib mesylate was analyzed. All patients had
bone marrow cytogenetic and FISH analysis at time of diagnosis and
afterwards at six months of starting Imatinib mesylate therapy. If they
achieved complete cytogenetic response then FISH analysis of
described probes was performed on yearly basis till end of study. If the
patients were in no or partial cytogenetic response group then both
cytogenetic study and FISH analysis were done every 6 monthly till
they achieve complete cytogenetic response.
Response of Imatinib mesylate was assessed according to standard
defined criteria i.e. Complete Hematological Response (CHR) is
defined as normalization of the bone marrow (blast cells less than or
equal to 5%) for at least four weeks and the peripheral leucocytes
count <10×109/L and platelets <450×109/L, without peripheral blasts,
promyelocytes and myelocytes), in addition to the disappearance of all
signs and symptoms of CML [13,14].
Cytogenetic response was based on the proportion of the Phpositive metaphases among at least 20 metaphases, and defined as
complete cytogenetic response; CCR (0% Ph-positive metaphases),
partial cytogenetic response; PCR (Ph-positive 1-35%) [14], and rest of
the other responses were merged in a single category; no cytogenetic
response; NCR (>35% Ph positive metaphases).
Major cytogenetic response characterized as combination of both
complete and partial cytogenetic responses (CCR+PCR). Clonal
Evolution (CE); defined as the appearance of additional chromosomal
aberration in at least two metaphases.

Statistical Analysis
All statistical analysis was computed with SPSS statistical software
(version 18.0.1). Data is presented as mean or median values; and
percentages. The prognostic value of various clonal evolutions on the
achievement of hematological and cytogenetic response by imatinib
mesylate was evaluated by the chi-square test.

Results
A total of 102 previously untreated patients were registered over a
period of 36 months. The median age of presentation was 35 years
(range, 15-65 years) among these 75 males and 27 were females (M:F is
2.7:1).
Median follow-up was 26 months (range, 3-36 months).

Fluorescence In-situ Hybridization (FISH), this technique allows
the visualization of specific nucleic acid sequence within a cellular
preparation. FISH involves the precise annealing of single stranded
fluorescent labeled DNA probe to complementary target sequences.
The hybridization of probes (Vysis, Abott Laboratories) with the
cellular DNA site is visible by direct detection by using fluorescence
microscopy.

Derivative 9q34 was the commonest chromosomal aberration in
this group; found in twelve cases by FISH at time of diagnosis. Other
detected chromosomal abnormalities were, trisomy 8 in three patients,
one patient had deletion 16 and one with addition 15. No other tested
probes identified any other chromosomal aberrations.

In this study, FISH analysis was performed in all of our patients for
detection of trisomy 8 and 19, Iso-chromosome 17 abnormalities with
loss of p53 gene and 20q deletions at time of diagnosis and follow-up.
Cases were also screened for derivative chromosome 9 only once at
time of diagnosis by using FISH.

Response Rate

The laboratory analyses were performed in Department of
Pathology & Microbiology; Section of Hematology and Section of
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Cases with derivative 9q34, the median age is 35 years. Among this
group eleven were males and one was female.

At the end of study, out of one hundred and two registered cases
only 78 completed at least six months of treatment and are evaluable
for cytogenetic response.
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Overall response rate of imatinib mesylate in chronic phase is
shown in Table1.
6 months

12 months

24 months

30 months

Response

N=60

N=78

N=78

N=78

Complete
hematologic
response

57

75

75

75

-95%

-96%

-96%

-96%

Cytogenetic Response
Complete
cytogenetic
response

31

29

28

35

-52%

-37%

-36%

-45%

52

53

48

-67%

-68%

-61%

19

26

25

30

-32%

-33%

-32%

-39%

Major cytogenetic 41
response
(CCR
+PCR)
-68%
No
cytogenetic
response (NCR)

Table 1: Response rate of imatinib mesylate in chronic phase of
chronic myeloid leukemia
In first six months of study period, 60 cases were registered and
cytogenetic analysis revealed major cytogenetic response in 41 cases
(31 patients achieved complete cytogenetic response) and 19 showed
no cytogenetic response.
At the completion of 36 months, out of 78 patients; 35 had complete
cytogenetic response, (48 achieved major cytogenetic response) and 18
had no cytogenetic response.
Twelve cases that had der 9q34 in addition to t (9; 22) at time of
presentation; only two of them achieved complete cytogenetic
response and 4 had no cytogenetic response and rests were in
evaluable due to loss to follow-up in subsequent visits. There was no
difference in cytogenetic response among patients with der9
chromosome and clonal evolution.
Three cases with trisomy 8, one with deletion 16 and addition 15
failed to achieve cytogenetic response with imatinib mesylate. In our
study, no patients acquire additional chromosomal aberration on
treatment.

identified in only three cases (2.9%) which are on contrary to prior
reports [15,16], including the one we reported earlier on patients with
CML treated with interferon prior to starting imatinib mesylate [17].
No other significant chromosomal aberrations were identified in our
group of patients either at time of enrollment in the study or on
follow-up cytogenetic analysis. This fact might be explained by that in
our study all cases were newly diagnosed CML, never received
interferon or any other drugs, as occurrence of clonal evolution in
interferon treated patients is a well-known phenomenon [18].
However, small subset of patients in this study and limited number of
probes for karyotypic analysis by FISH cannot be ignored.
In this series we reported major cytogenetic response rate in 68%
cases at 6 months follow-up and in 61% patients at completion of
study period. The fall in the response rate is due to loss of follow-up of
some cases which seen often in our setting. The rates of cytogenetic
responses in this study are in concordance to other reports [19,20],
and in fact more encouraging than our earlier publication [21], this
might be because in this group all cases are newly diagnosed CML
without any prior treatment and were in low risk group in contrast to
our previous report in which substantial number of cases were in
intermediate and high risk category according to Sokal prognostic
score [21].
Only two cases with derivative chromosome 9 achieved complete
cytogenetic response on long term follow-up, four were nonresponder and six were lost to follow-up. Similar to other reports
[22,23] it remain controversial whether patients with derivative
chromosome 9 have a different outcome if treated with imatinib
mesylate. Thus, derivative chromosome 9 was not yet an independent
significant factor for achieving cytogenetic response in our group of
patients as well [24,25].

Conclusion
Imatinib mesylate is effective first line therapy of chronic phase of
chronic myeloid leukemia especially in absence of clonal evolution.
Derivative chromosome 9 showed no prognostic significance in our
group; however, long term follow-up in larger cohorts of patients with
focus on specific chromosomal aberration including derivative
chromosome 9 are required in assessing the uncertain importance of
clonal evolution.
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